REG - GlaxoSmithKline PLC GlaxoSK Capital PLC - Publication of Supplementary Prospectus <Origin Href="QuoteRef">GSK.L</Origin> <Origin Href="QuoteRef">GSKCA.UL</Origin>

GSKAnnouncement

30/10/2014 06:13

RNS Number : 4156V
GlaxoSmithKline PLC
27 October 2014
Publication of Supplementary Prospectus
The following Supplementary Prospectus dated 27 October 2014, supplementing the Base Prospectus dated 4 August 2014, has been approved by the UK Listing Authority and is available for viewing:
GlaxoSmithKline plc and GlaxoSmithKline Capital plc 
15,000,000,000 Euro Medium Term Note Programme
Copies of the Supplementary Prospectus and the documents incorporated by reference therein have been submitted to the National Storage Mechanism and will shortly be available for inspection at:
http://www.morningstar.co.uk/uk/NSM.
The Supplementary Prospectus will also be available for viewing at:
http://www.gsk.com/en-gb/investors/stock-exchange-announcements/
For further information, please contact:
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Enquiries:
UK Media enquiries:
David Mawdsley
Simon Steel
(020) 8047 5502
(020) 8047 5502
European Analyst/Investor enquiries:
Gary Davies
Ziba Shamsi
(020) 8047 5503
(020) 8047 5543
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS AND BASE PROSPECTUS
Please note that the information contained in the Supplementary Prospectus and the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein. Your right to access this service is conditional upon complying with the above requirements.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
PDIPGGMPUUPCGRM